M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center

Not yet recruiting

Conditions: Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Discussion
Other: Electronic Health Record Review
Other: Questionnaire Administration

First Posted Date: 2021-10-27

Last Posted Date: 2025-03-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT05095948

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Magnetic Particle-ICG Lymph Node Mapping in Colorectal Cancer

Phase 1

Withdrawn

Conditions: Colorectal Cancer

Interventions: Device: FerroTraceTM
Drug: indocyanine green (ICG)

First Posted Date: 2021-10-26

Last Posted Date: 2023-09-28

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05092750

Patient-Informed Educational Intervention for the Improvement of Cervical Cancer Literacy

Withdrawn

Conditions: Stage IIA Cervical Cancer FIGO 2018
Stage IIA1 Cervical Cancer FIGO 2018
Stage IB1 Cervical Cancer FIGO 2018
Stage II Cervical Cancer FIGO 2018
Stage III Cervical Cancer FIGO 2018
Stage IIIC2 Cervical Cancer FIGO 2018
Stage IB Cervical Cancer FIGO 2018
Stage IB2 Cervical Cancer FIGO 2018
Stage IB3 Cervical Cancer FIGO 2018
Stage IIB Cervical Cancer FIGO 2018

Interventions: Other: Educational Intervention
Other: Survey Administration

First Posted Date: 2021-10-26

Last Posted Date: 2022-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05093712

Parent and Family Obesity Intervention in Reducing Obesity Risk in Racial Ethnic Minority Families

Not Applicable

Active, not recruiting

Conditions: Obesity-Related Malignant Neoplasm

Interventions: Behavioral: Behavioral Intervention
Other: Counseling
Procedure: Discussion
Other: Educational Intervention
Other: Informational Intervention
Other: Interview

First Posted Date: 2021-10-26

Last Posted Date: 2025-01-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT05094466

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Myeloma Multiple

Interventions: Drug: Lenalidomide
Drug: Belantamab mafodotin

First Posted Date: 2021-10-25

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 94

Registration Number: NCT05091372

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1

Recruiting

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage IV Breast Cancer AJCC v8
Advanced Breast Carcinoma
Advanced Endometrial Carcinoma
Advanced Fallopian Tube Carcinoma
Advanced Hepatocellular Carcinoma
Advanced Malignant Abdominal Neoplasm
Advanced Malignant Female Reproductive System Neoplasm

Interventions: Drug: Cabozantinib S-malate
Biological: Atezolizumab
Procedure: Tumor Treating Fields Therapy
Drug: Nab-paclitaxel

First Posted Date: 2021-10-25

Last Posted Date: 2025-04-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT05092373

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit

Suspended

Conditions: Recurrent Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Locally Advanced Malignant Solid Neoplasm

Interventions: Procedure: Electroencephalography
Other: Questionnaire Administration

First Posted Date: 2021-10-25

Last Posted Date: 2025-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT05091632

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Phase 1

Recruiting

Conditions: B-Cell Lymphoma
Myelodysplastic Syndromes (MDS)
Acute Myeloid Leukemia (AML)
Multiple Myeloma
Plasma Cell Leukemia
Hodgkin Lymphoma
T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia
Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia
Blastic Transformation of Chronic Myeloid Leukemia
Germ Cell Tumors

Interventions: Drug: CAR.70/IL15-transduced CB-NK cells
Drug: Cyclophosphamide
Drug: Fludarabine phosphate

First Posted Date: 2021-10-25

Last Posted Date: 2025-06-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT05092451

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation

Active, not recruiting

Conditions: Brain Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Procedure: Multiparametric Magnetic Resonance Imaging
Other: Questionnaire Administration

First Posted Date: 2021-10-21

Last Posted Date: 2025-04-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 9

Registration Number: NCT05087888

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy

Completed

Conditions: Gastric Carcinoma
Malignant Peritoneal Neoplasm
Carcinomatosis
Appendix Carcinoma
Colorectal Carcinoma
Malignant Solid Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Pain Assessment
Other: Questionnaire Administration

First Posted Date: 2021-10-19

Last Posted Date: 2024-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT05083338

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy